Press releases
-
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
-Final analysis shows ADSTILADRIN was well-tolerated with no new study drug-related adverse events — <4% of patients experienced Grade 3 AEs, there were no Grade 4 or 5 AEs — and no new safety signals reported In the overall study population at Month 60, the Kaplan-Meier (KM) estimated overall survival rate was 79.7% (95% CI 71.0-86.0), and the cystectomy-free survival […]
-
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
-Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal assures diversity of supply to meet future long-term plans for expanded availability of the gene therapy Two additional state-of-the-art manufacturing facilities for ADSTILADRIN are near completion in Finland and the U.S. Parsippany, NJ and King of Prussia, PA, U.S.– April 18, […]
-
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
-Expanded clinical trial program with ADSTILADRIN starts up in the United States Current clinical trial program of five multi-year studies to evaluate ADSTILADRIN demonstrate Ferring’s commitment to improve outcomes for patients across the spectrum of urothelial cancers Research will enlarge the body of evidence for ADSTILADRIN, the first and only FDA-approved intravesical non-replicating gene therapy for NMIBC Parsippany, NJ – April […]